CA2389982C - Inhibitions d'agents pathogenes a l'aide de bacteries probiotiques - Google Patents

Inhibitions d'agents pathogenes a l'aide de bacteries probiotiques Download PDF

Info

Publication number
CA2389982C
CA2389982C CA2389982A CA2389982A CA2389982C CA 2389982 C CA2389982 C CA 2389982C CA 2389982 A CA2389982 A CA 2389982A CA 2389982 A CA2389982 A CA 2389982A CA 2389982 C CA2389982 C CA 2389982C
Authority
CA
Canada
Prior art keywords
bacillus coagulans
strain
aminopeptidase
bacteria
species
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
CA2389982A
Other languages
English (en)
Other versions
CA2389982A1 (fr
Inventor
Sean Farmer
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Ganeden Biotech Inc
Original Assignee
Ganeden Biotech Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ganeden Biotech Inc filed Critical Ganeden Biotech Inc
Publication of CA2389982A1 publication Critical patent/CA2389982A1/fr
Application granted granted Critical
Publication of CA2389982C publication Critical patent/CA2389982C/fr
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/74—Bacteria
    • A61K35/741—Probiotics
    • A61K35/742—Spore-forming bacteria, e.g. Bacillus coagulans, Bacillus subtilis, clostridium or Lactobacillus sporogenes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/02—Local antiseptics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0034—Urogenital system, e.g. vagina, uterus, cervix, penis, scrotum, urethra, bladder; Personal lubricants

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Microbiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Mycology (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Zoology (AREA)
  • Molecular Biology (AREA)
  • Epidemiology (AREA)
  • Dermatology (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
CA2389982A 1999-11-08 2000-11-08 Inhibitions d'agents pathogenes a l'aide de bacteries probiotiques Expired - Lifetime CA2389982C (fr)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US16395999P 1999-11-08 1999-11-08
US60/163,959 1999-11-08
US19840400P 2000-04-19 2000-04-19
US60/198,404 2000-04-19
PCT/US2000/030737 WO2001034168A1 (fr) 1999-11-08 2000-11-08 Inhibitions d'agents pathogènes à l'aide de bactéries probiotiques

Publications (2)

Publication Number Publication Date
CA2389982A1 CA2389982A1 (fr) 2001-05-17
CA2389982C true CA2389982C (fr) 2015-06-16

Family

ID=26860126

Family Applications (1)

Application Number Title Priority Date Filing Date
CA2389982A Expired - Lifetime CA2389982C (fr) 1999-11-08 2000-11-08 Inhibitions d'agents pathogenes a l'aide de bacteries probiotiques

Country Status (5)

Country Link
EP (1) EP1229923A1 (fr)
JP (3) JP2003513649A (fr)
AU (1) AU785159B2 (fr)
CA (1) CA2389982C (fr)
WO (1) WO2001034168A1 (fr)

Families Citing this family (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU785159B2 (en) * 1997-04-18 2006-10-05 Ganeden Biotech, Inc. Inhibition of pathogens by bacillus coagulans strains
US7767203B2 (en) 1998-08-07 2010-08-03 Ganeden Biotech, Inc. Methods for the dietary management of irritable bowel syndrome and carbohydrate malabsorption
US6849256B1 (en) 1999-11-08 2005-02-01 Ganeden Biotech Incorporated Inhibition of pathogens by probiotic bacteria
FR2828407B1 (fr) * 2001-08-10 2005-06-24 Cobiotex Compositions a base de complexes bacteriens et leurs applications pour la prevention des infections nosocomiales
JP2004067599A (ja) * 2002-08-07 2004-03-04 Kunihiko Tominaga 腟内洗浄剤
US7854927B2 (en) * 2004-05-11 2010-12-21 Ganeden Biotech, Inc. Methods and compositions for the dietary management of autoimmune disorders
US8092793B2 (en) 2004-12-15 2012-01-10 Qingdao East Sea Pharmaceuticals, Ltd. Treating inflammatory bowel disease with live bacteria
CN101095698B (zh) 2006-06-26 2010-12-01 青岛东海药业有限公司 酪酸梭菌防治便臭毒素引起的相关症状和疾病的用途
CA2698190C (fr) 2007-08-29 2016-02-16 Ganeden Biotech, Inc. Produits cuits
WO2009051753A1 (fr) * 2007-10-16 2009-04-23 Ganeden Biotech, Inc. Compositions de boisson
US20090305387A1 (en) * 2008-01-30 2009-12-10 Ganeden Biotech, Inc. Compositions and methods for cleaning surfaces
AU2009305668B2 (en) 2008-10-16 2015-11-26 Ganeden Biotech, Inc. Probiotic grain-based compositions
AU2010242955B2 (en) * 2009-04-29 2016-02-04 Ganeden Biotech, Inc. Inactivated bacterial cell formulation
US11235008B2 (en) 2011-03-31 2022-02-01 Ganeden Biotech, Inc. Probiotic sports nutrition compositions
KR101769446B1 (ko) 2011-06-10 2017-08-22 (주)아모레퍼시픽 차나무 잎에서 분리한 신규 락토바실러스 플란타룸
KR101769445B1 (ko) 2011-06-10 2017-08-22 (주)아모레퍼시픽 차나무 잎에서 분리한 신규 락토바실러스 플란타룸
KR101769444B1 (ko) 2011-06-10 2017-08-22 (주)아모레퍼시픽 차나무 잎에서 분리한 신규 락토바실러스 플란타룸
KR101719197B1 (ko) * 2011-06-10 2017-03-24 (주)아모레퍼시픽 차나무 잎에서 분리한 신규 락토바실러스 플란타룸
CN113151045A (zh) 2011-06-10 2021-07-23 株式会社爱茉莉太平洋 分离自茶树叶的新型植物乳杆菌
JP5912610B2 (ja) 2012-02-07 2016-04-27 矢崎総業株式会社 ねじ締めブロックの係止構造
US9596861B2 (en) * 2013-12-24 2017-03-21 Sami Labs Limited Method of producing partially purified extracellular metabolite products from Bacillus coagulans and biological applications thereof
US11564879B2 (en) * 2016-11-23 2023-01-31 Gojo Industries, Inc. Sanitizer composition with probiotic/prebiotic active ingredient
WO2018226521A1 (fr) * 2017-06-09 2018-12-13 Muhammed Majeed Compositions et méthodes de réduction de la flatulence
CN115322931B (zh) * 2022-08-19 2023-04-25 华南农业大学 一株能够抑制α-葡萄糖苷酶和/或α-淀粉酶活性的凝结魏兹曼杆菌及其应用
CN115354002B (zh) * 2022-09-20 2023-12-19 微康益生菌(苏州)股份有限公司 一种凝结芽孢杆菌bc07、其用途及其抑菌剂、药物、食品和抑菌方法
CN116463258B (zh) * 2023-04-12 2024-01-09 山东威曼宠物食品有限公司 一种用于预防宠物腹泻的凝结芽孢杆菌King27及菌剂、制备方法和应用
CN117143770B (zh) * 2023-08-30 2024-03-08 广州格拉姆生物科技有限公司 一株凝结魏茨曼氏菌glm336及其应用

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IT1262927B (it) * 1992-01-14 1996-07-22 Consiglio Nazionale Ricerche Batteri sporgenti e loro impiego come probiotici
WO1994011492A1 (fr) * 1992-11-12 1994-05-26 Chr. Hansen's Laboratory, Inc. Procede modifiant de maniere avantageuse la microflore intestinale de la volaille
JP3381010B2 (ja) * 1994-05-10 2003-02-24 株式会社林原生物化学研究所 プロポリスエキスを含有する発酵物とその製造方法並びに用途
US5785990A (en) * 1995-07-10 1998-07-28 Merrick's, Inc. Feed fortifier and enhancer for preruminant calves and method of using same
JPH09194384A (ja) * 1996-01-19 1997-07-29 Snow Brand Milk Prod Co Ltd ミネラル吸収促進剤
ES2164299T5 (es) * 1997-01-09 2009-03-01 Societe Des Produits Nestle S.A. Producto cereal que contiene probioticos.
EP0975227B1 (fr) * 1997-04-18 2005-11-09 Ganeden Biotech, Inc. Utilisation topique de spores de bacilles probiotiques pour prevenir ou traiter les infections microbiennes
AU785159B2 (en) * 1997-04-18 2006-10-05 Ganeden Biotech, Inc. Inhibition of pathogens by bacillus coagulans strains
ES2317666T3 (es) * 1997-06-03 2009-04-16 Ganeden Biotech, Inc. Bacteria acida lactica probiotica para tratar infecciones bacterianas asociadas con el sids.
EP1067945B1 (fr) * 1998-04-01 2006-01-04 Ganeden Biotech, Inc. Methodes de reduction du cholesterol par des spores de bacillus coagulans, systemes et compositions associes
EP1102595A2 (fr) * 1998-08-07 2001-05-30 Ganeden Biotech, Inc. Procedes mettant en oeuvre des bacteries probiotiques non productrices d'acide lactique pour augmenter la solubilite de substances nutritives
US6461607B1 (en) * 1998-08-24 2002-10-08 Ganeden Biotech, Inc. Probiotic, lactic acid-producing bacteria and uses thereof
CA2368509A1 (fr) * 1999-04-14 2000-10-19 Ganeden Biotech, Inc. Procedes visant a inhiber des infections microbiennes associees a des produits hygieniques
EP1450610A4 (fr) * 2001-11-05 2006-03-29 Ganeden Biotech Inc Compositions probiotiques
JP5232404B2 (ja) * 2006-06-07 2013-07-10 第一三共ヘルスケア株式会社 有胞子性乳酸菌含有抗感冒ウイルス又は抗インフルエンザウイルス用組成物
AU2009305668B2 (en) * 2008-10-16 2015-11-26 Ganeden Biotech, Inc. Probiotic grain-based compositions

Also Published As

Publication number Publication date
WO2001034168A9 (fr) 2002-08-15
AU1590001A (en) 2001-06-06
JP2014001245A (ja) 2014-01-09
WO2001034168A1 (fr) 2001-05-17
JP2003513649A (ja) 2003-04-15
EP1229923A1 (fr) 2002-08-14
JP2012024092A (ja) 2012-02-09
CA2389982A1 (fr) 2001-05-17
AU785159B2 (en) 2006-10-05

Similar Documents

Publication Publication Date Title
US6849256B1 (en) Inhibition of pathogens by probiotic bacteria
CA2389982C (fr) Inhibitions d'agents pathogenes a l'aide de bacteries probiotiques
AU772332B2 (en) Probiotic, lactic acid-producing bacteria and uses thereof
US20110236359A1 (en) Antimicrobial Activity of Bacteriocin-Producing Lactic Acid Bacteria
US8440450B2 (en) Antibiotic-sensitive lactic acid bacteria strains
Mansour et al. Inhibition of Clostridium difficile in mice using a mixture of potential probiotic strains Enterococcus faecalis NM815, E. faecalis NM915, and E. faecium NM1015: novel candidates to control C. difficile infection (CDI)
CN113122466A (zh) 粪肠球菌及其应用
KR20050041808A (ko) 항암효과 및 항균활성이 뛰어난 신규 유산균 류코노스톡시트리움 km20
Narakaew et al. Preliminary characterization of Lactobacillus salivarius K7 for probiotic properties

Legal Events

Date Code Title Description
EEER Examination request
MKEX Expiry

Effective date: 20201109